It was found that
– 3E10 preferentially binds DNA single-strand tails,
– inhibits key steps in DNA single-strand and double-strand break repair, and
– sensitizes cultured tumor cells and human tumor xenografts to DNA-damaging therapy, including doxorubicin and radiation.
The results establish an approach to cancer therapy that is applicable to BRCA2-related malignancies such as breast, ovarian, and prostate cancers and also raise the possibility that lupus autoantibodies may be partly responsible for the intrinsic deficiencies in DNA repair and the unexpectedly low rates of breast, ovarian, and prostate cancers observed in SLE patients.
In an another study published by J. M. Ford, in Sci. Transl. Med. 4, 157fs38 (2012) shows that A lupus causing anti-DNA antibody penetrates living cells and targets DNA repair for therapeutic advantage in human cancer cells. http://stm.sciencemag.org/content/4/157/157fs38
These observations suggest
– the potential use of a lupus anti-DNA antibody in cancer therapy and
– identifies lupus autoantibodies as a potentially rich source of therapeutic agents.